GET DAILY SIGNALSMerck (MRK) Q3 Results: KEYTRUDA Momentum Supports Raised 2026 Outlook
Key Takeaways
- Merck reported third-quarter 2026 revenue of $18.1 billion, up 5% year over year (4% excluding foreign exchange), beating analyst estimates.
- Adjusted (non-GAAP) earnings per share came in at $2.49, well above consensus expectations of roughly $2.08–$2.12.
- The KEYTRUDA oncology franchise generated $8.6 billion (up 6%), including $830 million from the newer injectable formulation KEYTRUDA QLEX.
- Newer products added momentum, with WINREVAIR sales surging about 93% to $694 million and GARDASIL rising 14% to nearly $2 billion.
- Merck raised and narrowed its full-year 2026 outlook to revenue of $66.8–$67.3 billion and adjusted EPS of $2.77–$2.82.
- GAAP (Generally Accepted Accounting Principles) EPS declined to $2.04 from $2.32 a year earlier, reflecting higher investment and a one-time licensing charge.
- For additional context on this ticker, explore Major News, Today's Price Move, Price Targets, and Forecast.
- Discover automated trade ideas by exploring Trending AI Robots.
Why the Quarter Matters
Merck’s third-quarter report offers a useful window into how the company is navigating the coming loss of exclusivity for its flagship cancer drug KEYTRUDA, with key patents set to expire starting in 2028. I’m watching closely to see whether newer assets such as KEYTRUDA QLEX, WINREVAIR, and OHTUVAYRE can offset expected erosion in older products like JANUVIA and BRIDION. The latest numbers suggest the diversification effort is gaining traction, and management’s decision to raise full-year guidance adds further support for the growth narrative beyond the current blockbuster.
What the Numbers Show
Worldwide sales reached $18.1 billion for the quarter, a 5% increase from a year earlier (or 4% excluding foreign exchange). That result topped consensus estimates of roughly $17.2–$17.3 billion. Adjusted earnings per share of $2.49 also cleared the $2.08–$2.12 range analysts had projected. GAAP diluted EPS came in at $2.04, down from $2.32 in the prior-year period, largely because of higher operating expenses tied to launches and pipeline work plus a $0.12 per-share one-time charge linked to a licensing agreement with SciBrunch. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Segment performance included a 6% rise in KEYTRUDA-family revenue to $8.6 billion, a 93–94% jump in WINREVAIR to $694 million, a 14% increase in GARDASIL to about $2 billion, and a 4% gain in Animal Health to roughly $1.68 billion. Management noted that about $550 million of the quarter’s growth came from favorable purchase timing that is likely to reverse partly in the fourth quarter. Full-year 2026 guidance was narrowed to revenue of $66.8–$67.3 billion and lifted to adjusted EPS of $2.77–$2.82, from the earlier range of $2.66–$2.76.
Market Response
Shares of MRK moved higher after the release, with reports citing gains in the 2% to nearly 5% range in early and after-hours trading. The top- and bottom-line beat, strength in the newer KEYTRUDA QLEX formulation, and the improved profit outlook appear to have outweighed concerns about rising expenses and the year-over-year GAAP earnings decline. Commentary around clinical updates presented at the ESMO oncology conference also helped ease concerns about the late-stage pipeline. The modest shortfall in Animal Health did not shift the overall positive tone.
What to Watch Next
Looking forward, attention will focus on how quickly the newer products can sustain their launch trajectories as Merck prepares for the eventual patent expirations on KEYTRUDA. The under-the-skin KEYTRUDA QLEX formulation posted a record $830 million in quarterly sales, and management continues to highlight patient switching as an important lever for protecting oncology revenue. Operating expenses rose in the quarter due to launch and pipeline investments, and the company expects underlying expenses to grow at a mid-to-high single-digit rate. The $550 million timing benefit is expected to unwind largely in the fourth quarter.
Other items on the radar include the FDA’s acceptance of a biologics license application for sac-TMT in certain endometrial cancer patients, with a decision expected in mid-2027, plus ongoing international rollouts of WINREVAIR and CAPVAXIVE. Generic competition for JANUVIA and BRIDION and softer vaccination trends remain headwinds worth monitoring.
Using Tickeron’s AI Screener in My Research
When I want to compare Merck’s setup with other healthcare names or scan for similar earnings-driven moves, I turn to Tickeron’s AI Screener. The tool lets me filter by industry, technical patterns, fundamentals, and AI signals, which helps surface comparable ideas more efficiently than manual screening. It has become a regular part of how I review momentum across the sector after reports like this one.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
MRK in downward trend: 10-day moving average broke below 50-day moving average on October 13, 2026
The 10-day moving average for MRK crossed bearishly below the 50-day moving average on October 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 69%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MRK as a result. In 41 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 49%.
The Moving Average Convergence Divergence Histogram (MACD) for MRK turned negative on October 26, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 29 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 57%.
MRK moved below its 50-day moving average on October 23, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 51%.
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +4.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where MRK advanced for three days, in 192 of 339 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.
MRK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 32 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. MRK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 79 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.292) is normal, around the industry mean (-2.729). MRK's P/E Ratio (111.849) is considerably higher than the industry average of (20.997). Projected Growth (PEG Ratio) (2.716) is also within normal values, averaging (5.738). Dividend Yield (0.024) settles around the average of (0.040) among similar stocks. P/S Ratio (5.402) is also within normal values, averaging (4.033).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of human and animal health products
Industry PharmaceuticalsMajor
Advertisement